Approver SRL
0.5 FTEThe score of Approver shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +18 % Total assets -8 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Approver's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 54,652 € | ||||
| Equity | 389,088 € | ||||
| Cash | 276,296 € | ||||
| EBITDA | 123,984 € | ||||
| Total assets | 704,844 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 18 Dec 2025
- Year ended 30 Jun 2024filed on 17 Dec 2024
- Year ended 30 Jun 2023filed on 12 Dec 2023
- Year ended 30 Jun 2022filed on 20 Jan 2023
- Year ended 30 Jun 2021filed on 20 Dec 2021
Approver's financial analysis
- Solvency55.2%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Approver
Approver's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0872.752.055
- VAT number
- BE0872752055
- Peppol
- Registered · 0208:0872752055 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 25 Mar 2005
- Registered office
- 2500 Lier
- Size
- Micro · 0.5 FTE
- Latest accounts
- 2025 · filed on 18 Dec 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Approver (SRL) has been based in Lier since 2005, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 54,652 € and equity of 389,088 €; its revenue is not published. With 0.5 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 55.2%, above the median of its sector (44.2%).
Companies similar to Approver
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie ARS Sylvie Retail sale of pharmaceutical products Soignies · balance sheet 647,384 €
- Apotheek Acke Retail sale of pharmaceutical products Maldegem · balance sheet 668,623 €
- Apoteek Mortier Retail sale of pharmaceutical products Oudenaarde · balance sheet 589,824 €
- Verstraete Jeroen Apotheek Retail sale of pharmaceutical products Harelbeke · balance sheet 560,565 €
- ViOph.arma Retail sale of pharmaceutical products Frameries · balance sheet 689,435 €
- LS Pharma Retail sale of pharmaceutical products Gembloux · balance sheet 749,318 €
- PharmaSpace Retail sale of pharmaceutical products Ghent · balance sheet 495,059 €
- Kapelfarma Retail sale of pharmaceutical products Kontich · balance sheet 653,987 €
Frequently asked questions about Approver
What is the revenue of Approver?
Approver files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Approver?
In Belgium, the VAT number is the company number prefixed with BE: BE0872752055 for Approver, if the company is VAT-registered. Its company number (CBE) is 0872.752.055.
Where is the registered office of Approver?
According to the CBE register, the registered office of Approver is in 2500 Lier.
What is the equity of Approver?
At the close of the 2025 financial year, the equity of Approver amounts to 389,088 €, a solvency of 55.2% of total assets.
How many people work at Approver?
0.5 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Approver?
The register lists 2 active mandates at Approver. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Approver
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →